Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLR Allarity Therapeutics	$1.43 +51.9%	$0.99	$0.61 ▼ $5.94	$20.91M	0.08	3.83 million shs	385.40 million shs
BCEL Atreca	$0.09	$0.09	$0.05 ▼ $1.20	$3.57M	1.03	4.61 million shs	N/A
NXTC NextCure	$5.22	$5.21	$2.69 ▼ $19.80	$13.97M	1.25	53,412 shs	4,582 shs
TXMD TherapeuticsMD	$1.12 +1.0%	$1.14	$0.70 ▼ $2.44	$12.97M	0.42	236,137 shs	9,272 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLR Allarity Therapeutics	-0.35%	+3.44%	-7.72%	-0.92%	-82.84%
BCEL Atreca	0.00%	0.00%	0.00%	0.00%	0.00%
NXTC NextCure	+1.75%	-0.76%	-15.40%	-11.59%	-72.98%
TXMD TherapeuticsMD	+2.28%	-1.32%	-5.46%	-24.50%	-36.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLR Allarity Therapeutics	2.6366 of 5 stars	3.5	5.0	0.0	0.0	0.6	0.0	1.3
BCEL Atreca	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	3.9409 of 5 stars	3.3	3.0	0.0	4.3	0.0	1.7	1.3
TXMD TherapeuticsMD	0.1426 of 5 stars	0.0	3.0	0.0	0.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLR Allarity Therapeutics	3.00	Buy	$9.00	529.37% Upside
BCEL Atreca	0.00	N/A	N/A	N/A
NXTC NextCure	2.67	Moderate Buy	$25.50	388.51% Upside
TXMD TherapeuticsMD	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BCEL, ALLR, NXTC, and TXMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/28/2025	ALLR Allarity Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
7/15/2025	NXTC NextCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$36.00 ➝ $15.00
7/8/2025	NXTC NextCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
7/1/2025	NXTC NextCure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00

(Data available from 8/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	$1.62 per share	N/A
BCEL Atreca	N/A	N/A	N/A	N/A	$2.01 per share	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	$28.06 per share	N/A
TXMD TherapeuticsMD	$1.76M	7.37	N/A	N/A	$2.37 per share	0.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLR Allarity Therapeutics	-$24.51M	N/A	0.00	N/A	N/A	N/A	-173.31%	-102.57%	11/13/2025 (Estimated)
BCEL Atreca	-$97.16M	-$2.50	N/A	N/A	N/A	N/A	-157.90%	-71.39%	N/A
NXTC NextCure	-$55.65M	-$25.82	N/A	N/A	N/A	N/A	-106.62%	-85.20%	11/6/2025 (Estimated)
TXMD TherapeuticsMD	-$2.18M	N/A	0.00	∞	N/A	-17.94%	-2.01%	-1.40%	11/10/2025 (Estimated)

Latest BCEL, ALLR, NXTC, and TXMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q2 2025	ALLR Allarity Therapeutics	-$0.21	-$0.15	+$0.06	-$0.15	N/A	N/A
8/12/2025	Q2 2025	TXMD TherapeuticsMD	N/A	$0.05	N/A	$0.05	N/A	$0.95 million
8/7/2025	Q2 2025	NXTC NextCure	-$4.62	-$11.29	-$6.67	-$11.29	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLR Allarity Therapeutics	N/A	N/A	N/A	N/A	N/A
BCEL Atreca	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
TXMD TherapeuticsMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLR Allarity Therapeutics	N/A	2.31	2.31
BCEL Atreca	N/A	1.58	1.58
NXTC NextCure	N/A	3.71	3.71
TXMD TherapeuticsMD	N/A	2.89	2.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLR Allarity Therapeutics	11.53%
BCEL Atreca	37.47%
NXTC NextCure	42.65%
TXMD TherapeuticsMD	30.74%

Insider Ownership

Company	Insider Ownership
ALLR Allarity Therapeutics	0.01%
BCEL Atreca	11.30%
NXTC NextCure	17.90%
TXMD TherapeuticsMD	2.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLR Allarity Therapeutics	10	14.62 million	14.62 million	Not Optionable
BCEL Atreca	130	39.62 million	35.15 million	Optionable
NXTC NextCure	90	2.68 million	2.32 million	Optionable
TXMD TherapeuticsMD	420	11.57 million	11.31 million	Optionable

BCEL, ALLR, NXTC, and TXMD Headlines

Recent News About These Companies

TherapeuticsMD Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

TherapeuticsMD: Q2 Earnings Snapshot

August 12, 2025 | finance.yahoo.com

TherapeuticsMD Announces Second Quarter 2025 Financial Results

August 12, 2025 | businesswire.com

TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors despite daily gains

July 16, 2025 | marketwatch.com

Marlan D. Walker - TXMD | TherapeuticsMD Inc. - Wall Street Journal

June 29, 2025 | wsj.com

Mayne Pharma Files Legal Complaint Against TherapeuticsMD

June 1, 2025 | tipranks.com

TherapeuticsMD Announces First Quarter 2025 Financial Results

May 13, 2025 | businesswire.com

TherapeuticsMD Inc. stock rises Monday, still underperforms market

May 12, 2025 | marketwatch.com

TherapeuticsMD Inc. stock outperforms competitors despite losses on the day

April 8, 2025 | marketwatch.com

TherapeuticsMD Announces Full Year 2024 Financial Results

March 27, 2025 | businesswire.com

TherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo Finance

March 26, 2025 | finance.yahoo.com

TherapeuticsMD Inc’s Stock Drama: Could This Be a Game-Changer for TXMD Investors?

January 7, 2025 | bovnews.comB

TherapeuticsMD Inc (TXMD) Stock: A Deeper Look at Its True Potential

January 3, 2025 | bovnews.comB

TherapeuticsMD Inc. stock remains steady Friday, still outperforms market

December 27, 2024 | marketwatch.com

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gains

November 23, 2024 | marketwatch.com

TherapeuticsMD Shifts Focus with Lower Q3 Losses

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Reports Reduced Losses Amid Strategic Shift

November 14, 2024 | markets.businessinsider.com

TherapeuticsMD Announces Third Quarter 2024 Financial Results

November 13, 2024 | finance.yahoo.com

TherapeuticsMD Inc. stock remains steady Monday, underperforms market

November 12, 2024 | marketwatch.com

TherapeuticsMD (NASDAQ:TXMD) Stock, Option Chain

November 6, 2024 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCEL, ALLR, NXTC, and TXMD Company Descriptions

Allarity Therapeutics NASDAQ:ALLR

$1.43 +0.49 (+51.92%)

Closing price 04:00 PM Eastern

Extended Trading

$1.34 -0.10 (-6.64%)

As of 07:44 PM Eastern

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Atreca NASDAQ:BCEL

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

NextCure NASDAQ:NXTC

$5.22 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$5.20 -0.01 (-0.29%)

As of 04:04 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

TherapeuticsMD NASDAQ:TXMD

$1.12 +0.01 (+0.99%)

Closing price 03:55 PM Eastern

Extended Trading

$1.12 +0.00 (+0.36%)

As of 07:16 PM Eastern

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time